Jak Stat parhway

Reading File

Finding Sources

Searching PubMed

"JAK-STAT" signaling pathway

Reading File

Loading Image

Reading File

I now have comprehensive, well-sourced content to deliver a complete answer. Here is the full explanation:

JAK-STAT Pathway

Overview

The JAK-STAT pathway is a direct intracellular signaling system used by over 30 cytokines, growth hormones, and interferons to rapidly translate extracellular signals into changes in gene transcription -- without the need for second messengers like cAMP.

Key Components

JAK Family (Janus Kinases)

There are 4 mammalian JAKs:

JAK1 - broad roles in growth, development, hematopoiesis, inflammation
JAK2 - broad roles in growth, development, hematopoiesis, inflammation
JAK3 - primarily immune response
TYK2 - primarily immune response

Each JAK has a conserved kinase domain and a related pseudokinase regulatory domain. Crucially, JAKs are not intrinsic to the receptor -- they are cytoplasmic kinases that associate constitutively with cytokine receptor cytoplasmic tails.

STAT Family (Signal Transducers and Activators of Transcription)

There are 7 mammalian STATs: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6. Each shares:

An SH2 domain (for docking to phosphorylated receptors)
A DNA-binding domain
A transactivation domain

Step-by-Step Mechanism

JAK-STAT pathway showing cytokine receptor, JAK activation, STAT phosphorylation, dimerization, nuclear translocation, and regulation by SOCS/PIAS

Ligand binding - A cytokine (or growth hormone/interferon) binds its receptor on the cell surface.
Receptor dimerization/oligomerization - This brings two receptor chains together, drawing the constitutively associated JAKs into close proximity.
JAK trans-phosphorylation - The two JAKs reciprocally phosphorylate each other, activating their kinase activity.
Receptor tail phosphorylation - Activated JAKs phosphorylate specific tyrosine residues on the receptor's cytoplasmic tail, creating docking sites.
STAT recruitment - Cytoplasmic STAT proteins (inactive) are recruited to these phosphotyrosine docking sites via their SH2 domains.
STAT phosphorylation - Receptor-docked STATs are phosphorylated by JAKs on a key tyrosine residue.
STAT dimerization - Phosphorylated STATs detach from the receptor and dimerize (homo- or heterodimers) via mutual SH2-phosphotyrosine interactions.
Nuclear translocation - STAT dimers translocate to the nucleus.
Gene transcription - STAT dimers bind specific promoter motifs and activate transcription of target genes.

Cytokine-JAK-STAT Pairings

Diagram showing which cytokines activate which JAK-STAT combinations and their downstream effects

Cytokines	JAK pair	STATs activated	Effect
IL-20, TSLP, IFN-γ	JAK1 + JAK2	STAT1	Inflammation, T cell differentiation
IL-6, IL-11, IL-13, IL-27, G-CSF	JAK1 + JAK2 (+ TYK2)	STAT3, STAT6	Inflammation, wound healing, B cell function
IL-2, IL-4, IL-7, IL-9, IL-15, IL-21	JAK1 + JAK3	STAT1, 3, 5A/B, 6	T cell proliferation, Treg/B cell function
IFN-α, IFN-β, IL-10, IL-22	JAK1 + TYK2	STAT1, STAT2, STAT3	Antiviral immunity, inflammation
EPO, GH, GM-CSF, IL-3, IL-5, Leptin, Prolactin	JAK2 + JAK2	STAT3, STAT5A, STAT5B	Hematopoiesis, cell division, metabolism
IL-12, IL-23	JAK2 + TYK2	STAT3, STAT4	T cell differentiation, lymphocyte function

Negative Regulation (How the Signal Switches Off)

Three major mechanisms downregulate JAK-STAT signaling:

SOCS proteins (Suppressors of Cytokine Signaling) - 8 members (CIS, SOCS1-7). Induced by STAT activation itself (classical negative feedback). SOCS proteins inhibit JAK kinase activity directly or promote ubiquitin-proteasome degradation of JAKs and receptors. SOCS3 binds both JAK and the cytokine receptor to block STAT3 activation.
PIAS proteins (Protein Inhibitors of Activated STATs) - Form complexes with phosphorylated STAT dimers in the nucleus, either blocking their DNA binding or recruiting histone deacetylases to silence transcription.
Phosphotyrosine phosphatases (PTPs) - Including SHP1, SHP2, CD45, and T cell PTP -- these dephosphorylate JAKs, STATs, and receptor tails to terminate signaling.

Additional Crosstalk

JAK activation is not exclusively coupled to STATs. Active JAKs also recruit:

SHP2 and Shc/Grb2/Sos → activates Ras/MAPK cascade
p85 (PI3K regulatory subunit) → activates PI3K/AKT pathway
PLCγ → generates IP3/DAG second messengers

Clinical Relevance: JAK Inhibitors ("Jakinibs")

Because JAK-STAT signaling drives inflammation and immune cell proliferation, JAK inhibitors are a major therapeutic class:

Drug	JAK selectivity	Indications
Tofacitinib	JAK1/JAK3	Rheumatoid arthritis, UC, psoriatic arthritis
Baricitinib	JAK1/JAK2	RA, atopic dermatitis, COVID-19
Upadacitinib	JAK1-selective	RA, UC, Crohn's, atopic dermatitis
Ruxolitinib	JAK1/JAK2	Myelofibrosis, polycythemia vera
Filgotinib	JAK1-selective	RA, UC

Pathological JAK-STAT activation (via gain-of-function mutations, e.g., JAK2 V617F in myeloproliferative neoplasms) drives malignant hematopoiesis.

Sources: Firestein & Kelley's Textbook of Rheumatology, pp. 380-381 | Roitt's Essential Immunology, p. 256 | Harper's Illustrated Biochemistry, 32nd Ed, p. 528

This is a shared conversation. Sign in to Orris to start your own chat.